TILT-452

TILT-452 is a **preclinical cytokine-armed oncolytic adenovirus** being developed by TILT Biotherapeutics for solid tumors. The construct is described as an Ad5/3 chimeric adenovirus with tumor-selective replication features and encodes a **variant human interleukin-2** designed to preferentially stimulate IL-2 receptor signaling on effector lymphocytes over regulatory T cells. Mechanistically, it combines **direct oncolytic tumor cell killing** with **local immunostimulation**, aiming to enhance antitumor activity of tumor-infiltrating lymphocytes and natural killer cells in immunosuppressive solid-tumor microenvironments. Preclinical work has specifically highlighted ovarian cancer and pancreatic ductal adenocarcinoma models, and public pipeline summaries indicate the asset remains in preclinical development for solid tumors.

Other names

vIL-2 virusvIL2 virusvIL 2 virus